BI 3000202
/ Boehringer Ingelheim
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
December 10, 2025
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body
(clinicaltrials.gov)
- P1 | N=16 | Not yet recruiting | Sponsor: Boehringer Ingelheim
New P1 trial
November 27, 2025
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
(clinicaltrials.gov)
- P1 | N=14 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting
Enrollment closed
November 25, 2025
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
(clinicaltrials.gov)
- P1 | N=14 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting
Enrollment open
October 16, 2025
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
(clinicaltrials.gov)
- P1 | N=14 | Not yet recruiting | Sponsor: Boehringer Ingelheim
New P1 trial
August 05, 2025
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting
Enrollment open • Interferonopathies
1 to 5
Of
5
Go to page
1